Background: Alveolar soft part sarcomas (ASPS) are generally chemo- and radio-resistant mesenchymal tumours, with no standardized treatment guidelines. We describe the clinical behaviour of paediatric ASPS and compare these features to previously reported adult series. Patients and Methods: The clinical data of 51 children and adolescents with ASPS, prospectively enrolled in or treated according to seven European Paediatric trials were analysed. Results: Median age was 13 years [range: 2-21]. Primary sites included mostly limbs (63%). IRS post-surgical staging was: IRS-I (complete resection) 35%, II (microscopic residual disease) 20%, III (gross residual disease) 18% and IV (metastases) 27%. Only 3 of the 18 evaluable patients (17%) obtained a response to conventional chemotherapy. After a median follow-up of 126 months (range: 9-240), 14/18 patients with IRS-I tumour, 10/10 IRS-II, 7/9 IRS-III and 2/14 IRS-IV were alive in remission. Sunitinib treatment achieved two very good partial responses in four patients. Ten-year overall survival (OS) and event free survival (EFS) was 78.0±7% and 62.8±7% respectively. Stage IV, size >5cm and T2 tumours had a poorer outcome, but only IRS staging was an independent prognostic factor. Conclusions: ASPS is a very rare tumour frequently arising in adolescents and in the extremities, and chemo resistant. Local surgical control is critical. ASPS is a poorly chemo sensitive tumour. For IRS-III/IV tumours, delayed radical local therapies including surgery are essential. Metastatic patients had a poor prognosis but targeted therapies showed promising results. Pediatr Blood Cancer 2013;60:1826-1832.

, , , , ,
doi.org/10.1002/pbc.24683, hdl.handle.net/1765/69359
Pediatric Blood & Cancer
Department of Pediatrics

Orbach, D, Brennan, B, Casanova, M, Bergeron, C, Mosseri, V, Francotte, N, … Ferrari, A. (2013). Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups. Pediatric Blood & Cancer, 60(11), 1826–1832. doi:10.1002/pbc.24683